Abstract Number: 1795 • ACR Convergence 2022
Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease lacks recommendations on treatment strategies. This study reports on treatment modalities used in European tertiary hospitals for the management…Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…Abstract Number: 2192 • ACR Convergence 2022
Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…Abstract Number: 0105 • ACR Convergence 2022
Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
Background/Purpose: Immunosuppressive states can attenuate the immunogenicity of the COVID-19 vaccines. Some studies have shown an improved immune response with a supplemental primary dose. In…Abstract Number: 0309 • ACR Convergence 2022
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…Abstract Number: 0623 • ACR Convergence 2022
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
Background/Purpose: Despite advances in the treatment of Rheumatoid Arthritis (RA), synthetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness…Abstract Number: 0813 • ACR Convergence 2022
Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis
Background/Purpose: TRAPS is a rare hereditary autoinflammatory disease characterized by periodic fever and severe systemic and organ inflammation. Successful treatment was achieved with the interleukin-1β…Abstract Number: 0998 • ACR Convergence 2022
A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US
Background/Purpose: Systemic lupus erythematosus (SLE) patients present significant challenges in management. This study was to uncover real-world treatment patterns among moderate to severely active SLE…Abstract Number: 1162 • ACR Convergence 2022
Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment
Background/Purpose: There is little evidence about the effect of biological disease-modifying antirheumatic drugs (bDMARD) on gut dysbiosis in patients with axial SpA. Here we investigated…Abstract Number: 1433 • ACR Convergence 2022
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…Abstract Number: 1832 • ACR Convergence 2022
Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
Background/Purpose: This study aimed to demonstrate that there were no clinically meaningful differences between adalimumab-aqvh, a US Food and Drug Administration–approved biosimilar, and adalimumab in…Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…Abstract Number: 2198 • ACR Convergence 2022
How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
Background/Purpose: Uptake of biosimilars has been suboptimal in North America. In 2019, British Columbia (BC) became the first jurisdiction in North America to require patients…Abstract Number: 0133 • ACR Convergence 2022
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 67
- Next Page »